ViiV Healthcare's Tivicay Approved in Europe
January 21, 2014 at 06:55 AM EST
ViiV Healthcare today announced that the European Commission has approved Tivicay (dolutegravir), an integrase inhibitor, for use in combination with other anti-retroviral medicinal products for the treatment of HIV infected adults and adolescents above 12 years of age. See full press release (c) 2014 Benzinga.com. Benzinga does